Single and Multiple Dose Study of MK-1167 in Healthy Japanese Participants

INTERVENTION: In Part 1, a single oral dose of MK‐1167 3, 12 or 25 mg, or placebo will be administered. In Part 2, multiple oral doses of MK‐1167 or placebo will be administered at the dose level of 22 mg on Days 1‐2 and 5 mg on Days 3‐10. CONDITION: Dementia Alzheimer's type PRIMARY OUTCOME: Safety SECONDARY OUTCOME: Pharmacokinetics (Evaluation of plasma pharmacokinetics, comparison of plasma pharmacokinetics among CYP2C19 phenotypes) INCLUSION CRITERIA: Healthy Japanese males or postmenopausal females aged 18 to 45 years old